PDCD1LG2 and breast carcinoma: A previous study revealed that amplification of PD-L1 and PD-L2 are important biomarkers for immunotherapy, Gupta et al. found that the amplification of PD-L1/PD-L2 may play a potential mechanism of resistance to chemotherapy in breast cancer [46].